- Clinical Interests
- Drug hypersensitivity
- Eosinophilic disorders
- Food sensitivity
- Medical Education
- MD, Northwestern University Medical School
- Residency, Case Western Reserve University Hospital
- Board Certifications
- Allergy & Immunology
- Boston: Massachusetts General Hospital
- Waltham: Mass General Waltham
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - New York
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Adult and Pediatric
- Provider Gender
Dr. Banerji is an Associate Professor at Harvard Medical School and Training Program Director of the Allergy/Immunology fellowshop program at MGH. Dr. Banerji is an Allergist and Immunologist with a special interest in drug allergy and angioedema. She has a national reputation as an expert in these fields, with invited talks in both areas at regional, national and international conferences. Dr. Banerji has built a formal drug allergy program in the outpatient allergy clinic at MGH to better manage patients with drug hypersensitivity reactions. As part of this program, she collect standardized data on all patients we evaluate for drug hypersensitivity in order to identify risk factors for true hypersensitivity and improve drug allergy diagnosis with skin testing and challenges. In 2013, Dr. Banerji was invited to participate in an NIH workshop geared towards developing a prioritized research agenda on drug allergy and a summary of this meeting was published in August 2015 in the Journal of Allergy and Clinical Immunology. As an angioedema expert, Dr Banerji has collaborated with industry on five novel agents for hereditary angioedema and has published >10 peer-reviewed manuscripts including national and international guidelines for the management of angioedema. Dr. Banerji has actively participated as an investigator on multiple large clinical trials in hereditary angioedema, several of which were investigator initiated studies and including one study published by the NEJM in February 2017 as a first author.
Dr. Banerji's work focuses on drug allergy and angioedema. Specifically, Dr. Banerji has worked on improving the diagnosis and management of patients preseting with drug reactions to a variety of medications including antibiotics, aspirin, chemotherapeutic agents, monoclonal antibiotics and anesthetic agents. In the field of angioedema, Dr. Banerji has a particular interest in hereditary angioedema to improving care, improve quality of life and decreasing burden of disease.
A phase 3 clinical trial led by a Massachusetts General Hospital physician, finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema – a rare, potentially life-threatening disorder.
A clinical trial for a new drug to prevent attacks of hereditary angioedema – a rare disorder characterized by recurrent swelling of tissues in the face, hands, gastrointestinal tract and airway – has had promising results.
One morning in late March, 26-year-old Claire Branman learned that sometimes mothers don’t always know best. This realization came after she visited the allergy testing room on the second floor of Cox – an area of the MGH where patients can walk in with a medical question and walk out about three hours later with a definitive answer.
Clinical trials from two international research teams have shown that icatibant, a new drug that blocks the action of an inflammatory protein known as bradykinin, is safe and effective in treating acute attacks of hereditary angioedema, a potentially life-threatening condition.
55 Fruit Street
Boston, MA 02114-2696
40 Second Ave, Bldg 52
Waltham, MA 02451